KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 176 filers reported holding KITE PHARMA INC in Q2 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $14,076,000 | +56.8% | 78,285 | -9.6% | 0.03% | +63.2% |
| Q2 2017 | $8,976,000 | +33.2% | 86,578 | +0.8% | 0.02% | +35.7% |
| Q1 2017 | $6,740,000 | +86.1% | 85,869 | +6.3% | 0.01% | +100.0% |
| Q4 2016 | $3,622,000 | -21.9% | 80,769 | -2.7% | 0.01% | -30.0% |
| Q3 2016 | $4,635,000 | +12.7% | 82,969 | +0.9% | 0.01% | +11.1% |
| Q2 2016 | $4,113,000 | +30.3% | 82,269 | +19.7% | 0.01% | +28.6% |
| Q1 2016 | $3,156,000 | -4.2% | 68,753 | +28.6% | 0.01% | -12.5% |
| Q4 2015 | $3,295,000 | +12.6% | 53,471 | +1.7% | 0.01% | 0.0% |
| Q3 2015 | $2,927,000 | -8.8% | 52,571 | -0.2% | 0.01% | 0.0% |
| Q2 2015 | $3,211,000 | +224.3% | 52,671 | +206.8% | 0.01% | +300.0% |
| Q1 2015 | $990,000 | -2.3% | 17,168 | -2.3% | 0.00% | 0.0% |
| Q4 2014 | $1,013,000 | +123.6% | 17,568 | +10.5% | 0.00% | +100.0% |
| Q3 2014 | $453,000 | – | 15,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,358,084 | $105,736,000 | 48.63% |
| BAINCO INTERNATIONAL INVESTORS | 1,151,540 | $51,635,000 | 8.76% |
| Coastal Bridge Advisors, LLC | 250,040 | $11,212,000 | 4.36% |
| NEXTHERA CAPITAL LP | 150,000 | $6,726,000 | 3.94% |
| Casdin Capital, LLC | 94,000 | $4,215,000 | 3.48% |
| MENORA MIVTACHIM HOLDINGS LTD. | 1,258,899 | $56,449,000 | 2.90% |
| DIALECTIC CAPITAL MANAGEMENT, LP | 85,000 | $3,812,000 | 2.14% |
| SECTORAL ASSET MANAGEMENT INC | 372,223 | $16,690,000 | 1.85% |
| ARK Investment Management | 97,313 | $4,364,000 | 1.59% |
| BB BIOTECH AG | 800,000 | $35,872,000 | 1.33% |